Edwards Lifesciences expands litigation against CoreValve to US
This article was originally published in Clinica
The patent row between Edwards Lifesciences and CoreValve has expanded into the US, after Irvine, California-based Edwards filed a suit against its rival in a district court in Delaware. Edwards kicked off the legal dispute in May 2007 by initiating a lawsuit against CoreValve in Germany, and shortly after in the UK. The row centres around a group of patents owned by Edwards, known as the Andersen patents, which relates to transcatheter heart valve technology. Edwards alleges that CoreValve's ReValving system, which is designed to replace heart valves in a minimally-invasive manner, infringes these patents and is seeking injunctive relief and damages.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.